Lexicon Pharmaceuticals ( LXRX) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. This stock, rated D sell by TheStreet Ratings, is trading up 9.4% to $1.27 in recent trading. Today's Range: $1.22-$1.30 52-Week Range: $0.81-$2.17 Volume: 575,000 Three-Month Average Volume: 607,792 Shares of LXRX are spiking notably higher today after the company said the combination of LX4211 and the DPP-4 drug reduced blood sugar after meals in type 2 diabetes patients more than DPP-4 inhibitor did on a stand-alone basis. From a technical standpoint, LXRX is quickly approaching a breakout trade if this stock can manage to sustain a high-volume move and close above some past overhead resistance levels at $1.32 to $1.44. Look for a move and close above those levels on volume that's near or above 607,792 shares. If we get that action, then look for LXRX to challenge its August high of $1.85.